Skip to content

Rafael Holdings, Inc. RFL Deferred Tax Assets Research And Experimental Expenditures

Deferred Tax Assets Research And Experimental Expenditures at other companies

Trimas logo
TrimasTRS
$0-100%
NextNRG, Inc. Common Stock logo
NextNRG, Inc. Common StockNXXT
$367.23K+0.1%
Wrap Technologies logo
Wrap TechnologiesWRAP
$1.14M-41.1%
Minerals Technologies logo
Minerals TechnologiesMTX
$12.6M+14.5%
Sharplink, Inc.
 logo
Sharplink, Inc. SBET
$158K
Nuvation Bio logo
Nuvation BioNUVB
$78.79M-19.0%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept rfl:DeferredTaxAssetsResearchAndExperimentalExpenditures.

The official record: Rafael Holdings, Inc.’s 10-K, filed October 29, 2025, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s deferred tax assets research and experimental expenditures.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s deferred tax assets research and experimental expenditures?
Rafael Holdings, Inc. (RFL) reported deferred tax assets research and experimental expenditures of $29.12M in Q2 2025.
What does deferred tax assets research and experimental expenditures mean?
The tax benefit arising from the capitalization and amortization of research and experimental expenditures for tax purposes, which differs from financial reporting treatment. This asset represents future tax savings that the company expects to realize as it deducts these costs over time. It is a critical component for understanding the company's effective tax rate and cash flow management.